Heat shock protein 110 improves the anti-tumor effects of the cytotoxic T lymphocyte epitope E749-57 in mice

Cancer Biology and Therapy

Volumn 9, Issue 2, 2010, Pages

  Ren, Faliang ^a   Xu, Yunsheng ^a   Mao, Liwei ^c   Ou, Rongying ^a   Ding, Zhenzhen ^a   Zhang, Xueqi ^a   Tang, Jun ^b   Li, Bingxu ^a   Jia, Zhengcai ^b   Tian, Zhiqiang ^b   Ni, Bing ^b   Wu, Yuzhang ^b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c 309TH HOSPITAL OF PLA   (China)

Author keywords

E749 57; Heat shock protein 110; HPV16; Tumor; Vaccine

Indexed keywords

CHAPERONE; EPITOPE; FLUORESCEIN ISOTHIOCYANATE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 110; IMMUNOLOGICAL ADJUVANT; PROTEIN E7; CANCER VACCINE; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; VIRUS ANTIGEN; VIRUS VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CELL PROLIFERATION; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; LABELING INDEX; MOUSE; NONHUMAN; SPLEEN CELL; SURVIVAL TIME; TUMOR CELL; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG SCREENING; GERMFREE ANIMAL; HUMAN; IMMUNOLOGY; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROTEIN BINDING; TRANSPLANTATION; TUMOR CELL LINE; UTERINE CERVIX TUMOR; VACCINATION; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, VIRAL; CANCER VACCINES; CELL LINE, TUMOR; EPITOPES; FEMALE; HSP110 HEAT-SHOCK PROTEINS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECOMBINANT PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIRAL VACCINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 75749136919     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Cornelison TL. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment. Curr Opin Oncol 2000; 12:466-73.
2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.
3. Stanley MA. Human papillomavirus vaccines. Curr Opin Mol Ther 2002; 4:15-22.
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2:342-50.
5. Hampson L, El Hady ES, Moore JV, Kitchener H, Hampson IN. The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma. FASEB J 2001; 15:1445-7.
6. Weijzen S, Zlobin A, Braid M, Miele L, Kast WM. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J Cell Physiol 2003; 194:356-62.
7. Fausch SC, Da Silva DM, Eiben GL, Le Poole IC, Kast WM. HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci 2003; 8:81-91.
8. Hung CF, Monie A, Alvarez RD, Wu TC. DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 2007; 39:679-89.
9. Indrova M, Reinis M, Bubenik J, Jandlova T, Bieblova J, Vonka V, et al. Immunogenicity of dendritic cellbased HPV16 E6/E7 peptide vaccines: CTL activation and protective effects. Folia Biol (Praha) 2004; 50:184-93.
10. Lazoura E, Apostolopoulos V. Insights into peptidebased vaccine design for cancer immunotherapy. Curr Med Chem 2005; 12:1481-94.
11. Scheibenbogen C, Letsch A, Schmittel A, Asemissen AM, Thiel E, Keilholz U. Rational peptide-based tumour vaccine development and T cell monitoring. Semin Cancer Biol 2003; 13:423-9.
12. Brinkman JA, Hughes SH, Stone P, Caffrey AS, Muderspach LI, Roman LD, et al. Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 2007; 23:337-52.
13. Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008; 122:247-59.
14. Lazoura E, Apostolopoulos V. Rational Peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem 2005; 12:629-39.
15. Patel DM, Arnold PY, White GA, Nardella JP, Mannie MD. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition. J Immunol 1999; 163:5201-10.
16. + T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion. J Immunol 2006; 177:2976-84.
17. Przepiorka D, Srivastava PK. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol Med Today 1998; 4:478-84.
18. Heike M, Noll B, Meyer zum Buschenfelde KH. Heat shock protein-peptide complexes for use in vaccines. J Leukoc Biol 1996; 60:153-8.
19. Srivastava PK. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep 2005; 7:104-8.
20. Hickman-Miller HD, Hildebrand WH. The immune response under stress: the role of HSP-derived peptides. Trends Immunol 2004; 25:427-33.
21. Moseley P. Stress proteins and the immune response. Immunopharmacology 2000; 48:299-302.
22. Suzue K, Zhou X, Eisen HN, Young RA. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proceedings of the National Academy of Sciences of the United States of America 1997; 94:13146-51.
23. Castellino F, Boucher PE, Eichelberg K, Mayhew M, Rothman JE, Houghton AN, et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. The Journal of experimental medicine 2000; 191:1957-64.
24. Manjili MH, Park J, Facciponte JG, Subjeck JR. HSP110 induces "danger signals" upon interaction with antigen presenting cells and mouse mammary carcinoma. Immunobiology 2005; 210:295-303.
25. Levey DL, Brander C, Srivastava PK. The potential of heat shock protein-peptide complexes as a therapeutic HIV vaccine. J HIV Ther 2005; 10:56-9.
26. Aalamian M, Fuchs E, Gupta R, Levey DL. Autologous renal cell cancer vaccines using heat shock proteinpeptide complexes. Urol Oncol 2006; 24:425-33.
27. Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 2006; 55:958-68.
28. Srivastava PK, Callahan MK, Mauri MM. Treating human cancers with heat shock protein-peptide complexes: the road ahead. Expert Opin Biol Ther 2009; 9:179-86.
29. Kim HL, Sun X, Subjeck JR, Wang XY. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol Immunother 2007; 56:1097-105.
30. Navaratnam M, Deshpande MS, Hariharan MJ, Zatechka DS Jr, Srikumaran S. Heat shock proteinpeptide complexes elicit cytotoxic T-lymphocyte and antibody responses specific for bovine herpesvirus 1. Vaccine 2001; 19:1425-34.
31. Srivastava PK, Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol 1994; 6:728-32.
32. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997; 186:1315-22.
33. Murshid A, Gong J, Calderwood SK. Heat-shock proteins in cancer vaccines: agents of antigen crosspresentation. Expert Rev Vaccines 2008; 7:1019-30.
34. Bolhassani A, Rafati S. Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines 2008; 7:1185-99.
35. Roman E, Moreno C. Synthetic peptides non-covalently bound to bacterial hsp 70 elicit peptide-specific T-cell responses in vivo. Immunology 1996; 88:487-92.
36. Castelli C, Ciupitu AM, Rini F, Rivoltini L, Mazzocchi A, Kiessling R, et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001; 61:222-7.
37. Park J, Easton DP, Chen X, MacDonald IJ, Wang XY, Subjeck JR. The chaperoning properties of mouse grp170, a member of the third family of hsp70 related proteins. Biochemistry 2003; 42:14893-902.
38. Wang XY, Chen X, Manjili MH, Repasky E, Henderson R, Subjeck JR. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100. Cancer Res 2003; 63:2553-60.
39. Wang XY, Kazim L, Repasky EA, Subjeck JR. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J Immunol 2001; 166:490-7.
40. Goeckeler JL, Petruso AP, Aguirre J, Clement CC, Chiosis G, Brodsky JL. The yeast Hsp110, Sse1p, exhibits high-affinity peptide binding. FEBS Lett 2008; 582:2393-6.
41. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23:2242-9.
42. Khammanivong V, Liu XS, Liu WJ, Rodda SJ, Leggatt GR, Tindle RW, et al. Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. Immunol Cell Biol 2003; 81:1-7.
43. Sadovnikova E, Zhu X, Collins SM, Zhou J, Vousden K, Crawford L, et al. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein. Int Immunol 1994; 6:289-96.
44. Cui Z, Qiu F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother 2006; 55:1267-79.
45. Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, Brown RG, et al. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006; 24:5235-44.
46. Lee-Yoon D, Easton D, Murawski M, Burd R, Subjeck JR. Identification of a major subfamily of large hsp70-like proteins through the cloning of the mammalian 110-kDa heat shock protein. J Biol Chem 1995; 270:15725-33.
47. Oh HJ, Easton D, Murawski M, Kaneko Y, Subjeck JR. The chaperoning activity of hsp110. Identification of functional domains by use of targeted deletions. J Biol Chem 1999; 274:15712-8.
48. Easton DP, Kaneko Y, Subjeck JR. The hsp110 and Grp1 70 stress proteins: newly recognized relatives of the Hsp70s. Cell Stress Chaperones 2000; 5:276-90.
49. Li Z. In vitro reconstitution of heat shock protein-peptide complexes for generating peptide-specific vaccines against cancers and infectious diseases. Methods 2004; 32:25-8.
50. Kurotaki T, Tamura Y, Ueda G, Oura J, Kutomi G, Hirohashi Y, et al. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J Immunol 2007; 179:1803-13.
51. Udono H, Yamano T, Kawabata Y, Ueda M, Yui K. Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70. Int Immunol 2001; 13:1233-42.
52. Manjili MH, Henderson R, Wang XY, Chen X, Li Y, Repasky E, et al. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res 2002; 62:1737-42.
53. Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 2003; 171:4054-61.
54. Li Y, Subjeck J, Yang G, Repasky E, Wang XY. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine 2006; 24:5360-70.
55. Srivastava RM, Varalakshmi C, Khar A. The ischemiaresponsive protein 94 (Irp94) activates dendritic cells through NK cell receptor protein-2/NK group 2 member D (NKR-P2/NKG2D) leading to their maturation. J Immunol 2008; 180:1117-30.
56. Facciponte JG, Wang XY, Subjeck JR. Hsp110 and Grp170, members of the Hsp70 superfamily, bind to scavenger receptor-A and scavenger receptor expressed by endothelial cells-I. Eur J Immunol 2007; 37:2268-79.
57. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000; 6:435-42.
58. + cells in vivo. J Immunol 2000; 165:6029-35.
59. Singh-Jasuja H, Scherer HU, Hilf N, Arnold-Schild D, Rammensee HG, Toes RE, et al. The heat shock protein gp96 induces maturation of dendritic cells and downregulation of its receptor. Eur J Immunol 2000; 30:2211-5.
60. Singh-Jasuja H, Hilf N, Scherer HU, Arnold-Schild D, Rammensee HG, Toes RE, et al. The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells. Cell stress & chaperones 2000; 5:462-70.
61. Park JE, Facciponte J, Chen X, MacDonald I, Repasky EA, Manjili MH, et al. Chaperoning function of stress protein grp170, a member of the hsp70 superfamily, is responsible for its immunoadjuvant activity. Cancer Res 2006; 66:1161-8.
62. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56:21-6.
63. Ni B, Gao W, Zhu B, Lin Z, Jia Z, Zhou W, et al. Induction of specific human primary immune responses to a Semliki Forest virus-based tumor vaccine in a Trimera mouse model. Cancer Immunol Immunother 2005; 54:489-98.
64. Ni B, Lin Z, Zhou L, Wang L, Jia Z, Zhou W, et al. Induction of P815 tumor immunity by DNA-based recombinant Semliki Forest virus or replicon DNA expressing the P1A gene. Cancer Detect Prev 2004; 28:418-25.